Month: May 2022

In connection with the business combination between The Drilling Company of 1972 A/S (“Maersk Drilling”) and Noble Corporation (“Noble”, and together with Maersk Drilling, the “Parties”) announced on 10 November 2021 (link) (the “Business Combination”), Noble has made a filing on Form 8-K (link) providing an update on the ongoing merger control process for obtaining clearance in the UK for the Business Combination. The process remains ongoing following the UK Competition and Markets Authority’s (“UK CMA”) Phase 1 decision on 22 April 2022 pursuant to which the UK CMA stated that the transaction gives rise to a realistic prospect of a substantial lessening of competition and that a remedy to address such effect would be required to avoid a reference to a Phase 2 review. As a result, Noble and possibly Maersk Drilling plan to offer to divest...

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 2, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced the appointment of Dr. Brandi Howard as Chief Clinical Officer and member of the company’s Executive Committee, effective May 9, 2022. Dr. Howard, who brings to ObsEva more than 20 years of women’s health expertise, will be responsible for the Company’s clinical development and medical affairs strategy. She succeeds Dr. Elizabeth Garner, who will be departing the Company on May 6, 2022 to pursue a new opportunity. To help ensure a smooth transition, Dr. Garner has agreed to provide advisory consulting services to ObsEva on an as needed basis. “We are pleased to welcome Brandi, a recognized...

EL DORADO, Ark., May 02, 2022 (GLOBE NEWSWIRE) — Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), an innovative technology and lithium project development company, today announced the commencement of a Preliminary Feasibility Study (PFS) at its South West Arkansas Lithium Project (the “Project”), which is located approximately 35 miles west of the Company’s Lanxess project. Standard Lithium recently completed a Preliminary Economic Assessment at the Project (see Company news release Nov 26, 2021), and on the basis of positive project economics and favorable project fundamentals, the Company has commissioned a team of technical experts to complete a NI43-101 compliant PFS for the Project. The PFS will consider an integrated project including; brine supply and injection wells,...

REDWOOD CITY, Calif., May 01, 2022 (GLOBE NEWSWIRE) — Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced the pricing of an underwritten registered direct offering of an aggregate of 18,026,315 shares of its common stock at an offering price of $3.80 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase up to 12,921,055 shares of common stock at an offering price of $3.799 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. Certain of the pre-funded warrants offered to investors are only exercisable upon...

Trondheim, 1 May 2022: Reference is made to the stock exchange notice dated 1 March 2022, where NORBIT announced to be in exclusive negotiations regarding a minor add-on acquisition of an undisclosed international maritime technology company. Completion of the transaction was subject to a number of conditions, of which some were not fulfilled satisfactorily as considered by NORBIT. Accordingly, NORBIT has decided to rescind the share purchase agreement and withdraw from the process. NORBIT will continue to explore value-accretive acquisitions through its defined criteria to accelerate growth beyond its organic revenue target of NOK 1.5 billion in 2024. For more information, please contact:Per Jørgen Weisethaunet, CEO, +47 959 62 915Per Kristian Reppe, CFO, +47 900 33 203 About NORBIT NORBIT is a global provider of tailored technology...

Results Presented Today at the Pediatric Endocrine Society’s 2022 Annual MeetingHighly significant ~75% reduction in hypoglycemia events at anticipated therapeutic doses ≥50% improvement in hypoglycemia in 100% of patients in high-dose cohort, with no adverse drug reactions or clinically significant hyperglycemia Study exceeded expectations for correction of hypoglycemia across multiple metrics, including hypoglycemia events and time in hypoglycemia Predictable and dose-dependent exposures with a clear dose-response Good safety and tolerability across all doses with no study discontinuations or adverse drug reactions Results are Phase 3 enabling and demonstrate the potential for RZ358 to be used as a monotherapy as well as a potential universal therapy for all forms of hyperinsulinism Company hosting Analyst and Investor Conference...

– Poster highlights analysis of baseline neutralizing antibodies to AAV.7m8 and impact on ADVM-022 efficacy and safety in OPTIC – – Reductions in mean annualized anti-VEGF injections ranged from 81% in all patients to 94% in those with NAbs

SAN DIEGO, May 01, 2022 (GLOBE NEWSWIRE) — Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a five-week awareness campaign to highlight important and impactful work being done to help those suffering from Systemic Lupus Erythematosus (SLE). For each of the five weeks in the month of May, Exagen will focus on a different theme that, when combined, provides a holistic view of the work being done within the lupus community. These themes include:Diagnosis: highlighting the role and importance of an early and accurate diagnosis. Advocacy: sharing the stories of patient advocates, and their impact on the community. Community: shedding light on the regional and local efforts bringing people together. Research: providing insight into...

— Data Demonstrate Rapid and Complete Wound Healing, with Six of Eight (75%) Patients Achieving Complete Healing within Four Weeks; All Remained Healed Through End of Follow-Up —— All Patients with Pain at Baseline Reported Zero Pain by Week 3 —— KPI-012 was Well-Tolerated with No Significant Safety Issues Observed —— On Track to Submit Investigational New Drug Application (IND) and Initiate Phase 2/3 Trial in 4Q 2022 — ARLINGTON, Mass., May 01, 2022 (GLOBE NEWSWIRE) — Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported clinical data from a Phase 1b trial of KPI-012, its novel, cell-free secretome therapy for the treatment of...